Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Effectiveness of taxane- or anthracyclin-based compared to taxane- and anthracycline-free first-line treatments of patients with metastatic breast cancer treated by German office-based medical oncologists. Data from the TMK Registry Group.

Marschner, N., Dörfel, S., Meyer, D., Petersen, V., Frank, M., Jänicke, M., Tesch, H., 2013.

The Breast 22 (suppl 3) (P41). doi:10.1016/S0960-9776(13)70055-9

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ABC2 / Journal: The Breast
TMK
2013
Overall survival and sequential treatment of patients with metastatic breast cancer treated by German office-based medical oncologists – outcome data from the TMK Registry Group.

Marschner, N., Däßler, K.-U., Müller-Hagen, S., Kruggel, L., Jänicke, M., Tesch, H., 2013.

The Breast 22 (suppl 3) (V39). doi:10.1016/S0960-9776(13)70052-3

Abstract

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ABC2 / Journal: The Breast
TMK
2013
Overall survival and sequential treatment of patients with advanced NSCLC in German outpatients centres – data from the clinical TLK Registry.

Marschner, N., Bertram, M., Kopfmann, S., von Verschuer, U. von, Tessen, H.W., 2013.

Onkologie 36 (suppl 7)(V118), 29. doi:10.1159/000356365

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Onkologie
TLK
2013
Response to 1st-line Treatment with BR or R-CHOP in Patients with Indolent non-Hodgkin’s Lymphoma: First Outcome Data from the German Prospective TLN Registry.

Knauf, W.U., Abenhardt, W., Hansen, R., Grugel, R., Harde, J., Marschner, N., 2013.

Blood 122(21), 3036.

Abstract

Download

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: ASH / Journal: Blood
TLN
2013
Response to 1st-line Treatment with BR or FCR in Patients with Chronic Lymphocytic Leukaemia: First Outcome Data from the German Prospective TLN Registry.

Knauf, W.U., Abenhardt, W., Engel, E., Grugel, R., Harde, J., Marschner, N., 2013.

Blood 122(21), 4181.

Abstract

Download

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: ASH / Journal: Blood
TLN
2013
Therapy of relapsed/ refractory multiple myeloma with a combination of Lenalidomide plus Dexamethasone: First interim analysis of the non-interventional study “Revlimid.”

Knauf, W., Aldaoud, A., Groschek, M., Teichmann, B., Harde, J., Hasskarl, J., 2013.

Onkologie 36 (suppl. 7)(P532), 155. doi:10.1159/000356365

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Onkologie
Revlimid-NIS
2013
Treatment of indolent NHL by office-based haematologists in Germany: R-bendmustine replaces R-CHOP as “Standard of Care.”

Knauf, W., Abenhardt, W., Nusch, A., Grugel, R., Marschner, N., 2013.

Hematol Oncol 31 (Suppl. I)(Abstract 467), 248. doi:10.1002/hon.2059

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: ICML / Journal: Hematological Oncology
TLN
2013
Treatment of Elderly Patients with CLL: Does Bendamustine Replace Chlorambucil as “Standard of Care”?

Knauf, W., Abenhardt, W., Nusch, A., Grugel, R., Marschner, N., 2013.

Hematol Oncol 31 (Suppl. I)(Abstract 372), 219. doi:10.1002/hon.2059

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: ICML / Journal: Hematological Oncology
TLN
2013
VMP in 1st-Line Treatment of Non-Transplant Patients with Multiple Myeloma in Routine Practice: First Follow-Up Data from the Tumour Registry Lymphatic Neoplasms.

Knauf, W., Abenhardt, W., Harich, H.-D., Schlag, R., Grugel, R., Marschner, N., 2013.

Onkologie 36 (suppl 7)(P528), 152–153. doi:10.1159/000356365

Abstract

Download

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Onkologie
TLN
2013
A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial of immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.

Kasper, S., Overkamp, F., Moehler, M., Kullmann, F., Lang, H., Schoen, M., Smith-Machnow, V., Hegewisch-Becker, S., Seehofer, D., Bechstein, W., Heike, M., Voehringer, M., Heinemann, V., Greil, R., Geissler, M., Lordick, F., Peeters, M., Van Cutsem, E., Galle, P.R., Schimanski, C.C., 2013.

J Clin Oncol 31(suppl; abstr TPS3124). doi: 10.1200/jco.2013.31.15_suppl.tps3124

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: ASCO / Journal: Journal of Clinical Oncology
LICC
2013